NCT04751383 2026-01-21Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed OsteosarcomaNational Cancer Institute (NCI)Phase 1 Completed12 enrolled 12 charts